Abstract

AN OPEN LABEL, PROSPECTIVE STUDY TO COMPARE THE EFFECT OF FIXED DOSE COMBINATION OF METFORMIN AND PIOGLITAZONE VERSUS FIXED DOSE COMBINATION OF METFORMIN AND GLICLAZIDE ON LIPID PROFILE PARAMETERS IN TYPE-II DIABETES PATIENT.

*Dr. Lomte D. B.

ABSTRACT

Objective: To evaluate and compare the effect of Fixed Dose combination of metformin and pioglitazone versus metformin and Gliclazide on lipid profile parameters in Type-II diabetes patients with deranged Lipid Profile. Methods: Patients (n=60) of type-2 Diabetes with deranged lipid profile parameters consisting of 31 males and 29 females between 35-59 yrs were studied. They were divided into two groups of 30 each. Group-I: Metformin +Pioglitazone and Group-II: Metformin +Gliclazide. Each patient was assessed for a period of 16 weeks. Lipid profile parameters were assessed before study and at the end of the study. Statistical analysis was carried out by using paired 't' test for comparing the effect of Metformin + Pioglitazone, and Metformin+ Gliclazide on lipid profile parameters before and after therapy. For comparing between groups after the therapy ANOVA (Analysis of Variance) test was applied. Results: There were significant reduction in the studied lipid profile parameters in both groups after 16 weeks of therapy (P<0.05). The inter-group comparison showed that the combination: Metformin +Pioglitazone (FDC) group has more significant (P<0.05) effect on the Serum Triglycerides (TG), High density lipoprotein cholesterol (HDL-C) while the combination: Metformin +Gliclazide has more significant (P<0.05) effect on Low density lipoprotein cholesterol (LDL-C).

Keywords: Metformin, Pioglitazone, Gliclazide, Lipid profile, Serum Triglycerides, High density lipoprotein cholesterol (HDL-C), Low density lipoprotein cholesterol (LDL-C).